Medicare Enrolled
Dr. Sucharu Prakash, MD
Medical Oncology · Paris, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Prakash from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Prakash? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Prakash
Dr. Sucharu Prakash is a medical oncology in Paris, TX, with 19 years in practice. Based on federal Medicare data, Dr. Prakash performed 231,844 Medicare services across 6,995 unique beneficiaries.
Between the years covered by Open Payments, Dr. Prakash received a total of $131,454 from 38 pharmaceutical and/or device companies across 167 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Prakash is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 2% volume in TX$ $131,454 industry payments
Medicare Practice Summary
Medicare Utilization ↗231,844
Medicare services
Top 2% in TX for medical oncology
6,995
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~12,202 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 58,650 | $0 | $5 |
| Anti-nausea injection (fosaprepitant) | 35,700 | $0 | $5 |
| Oxaliplatin chemotherapy injection | 34,300 | $0 | $33 |
| Contrast dye for imaging (iodine-based) | 15,744 | $0 | $3 |
| Pembrolizumab injection (Keytruda) | 12,900 | $43 | $137 |
| Paclitaxel chemotherapy injection | 9,522 | $0 | $8 |
| Darbepoetin injection (Aranesp) for anemia | 9,430 | $2 | $20 |
| Dexamethasone injection (steroid) | 6,287 | $0 | $1 |
| Immune globulin infusion (Octagam) | 5,850 | $34 | $234 |
| Denosumab injection (Prolia/Xgeva) | 4,920 | $19 | $66 |
| Anti-nausea injection (Aloxi/palonosetron) | 3,310 | $1 | $114 |
| Injection, docetaxel, 1 mg | 3,173 | $1 | $66 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 3,120 | $22 | $155 |
| Injection, atropine sulfate, 0.01 mg | 2,360 | $0 | $1 |
| Injection, leucovorin calcium, per 50 mg | 2,082 | $3 | $25 |
| Injection, granisetron hydrochloride, 100 mcg | 1,860 | $0 | $24 |
| Epoetin alfa injection (Retacrit) for anemia | 1,820 | $6 | $28 |
| Blood draw (venipuncture) | 1,750 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,674 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,504 | $10 | $64 |
| Injection, fluorouracil, 500 mg | 1,430 | $2 | $13 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,320 | $23 | $181 |
| Office visit, established patient (30-39 min) | 964 | $92 | $368 |
| Injection of additional new drug or substance into vein | 948 | $11 | $108 |
| Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | 810 | $14 | $126 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 766 | $21 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 650 | $97 | $707 |
| Office visit, established patient (20-29 min) | 569 | $64 | $250 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 468 | $75 | $1,348 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 389 | $47 | $313 |
| Injection, zoledronic acid, 1 mg | 382 | $6 | $431 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 370 | $3 | $373 |
| Injection, carboplatin, 50 mg | 351 | $2 | $300 |
| Drug injection, under skin or into muscle | 336 | $10 | $96 |
| Cyclophosphamide, 100 mg | 311 | $16 | $203 |
| Injection, potassium chloride, per 2 meq | 300 | $0 | $1 |
| Lactate dehydrogenase (enzyme) level | 292 | $6 | $31 |
| Injection, diphenhydramine hcl, up to 50 mg | 260 | $1 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 245 | $48 | $344 |
| Microscopic examination for white blood cells with manual cell count | 241 | $4 | $22 |
| Complete blood count (CBC), automated | 241 | $6 | $34 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 220 | $272 | $2,762 |
| Ferritin level test (iron stores) | 208 | $13 | $60 |
| Iron level test | 206 | $6 | $27 |
| Iron binding capacity test | 206 | $9 | $35 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 187 | $53 | $211 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 185 | $73 | $70 |
| Administration of chemotherapy into vein, each additional hour | 184 | $21 | $161 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 178 | $15 | $100 |
| Infusion, normal saline solution , 1000 cc | 158 | $2 | $19 |
| New patient office visit, complex (60-74 min) | 156 | $156 | $709 |
| Ct scan of chest with contrast | 152 | $48 | $821 |
| Reticulated (young) platelet measurement | 140 | $35 | $143 |
| Administration of additional new drug or substance into vein using push technique | 140 | $41 | $289 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 137 | $15 | $94 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 135 | $24 | $145 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 132 | $123 | $500 |
| Injection, magnesium sulfate, per 500 mg | 118 | $1 | $6 |
| Irrigation of implanted venous access drug delivery device | 114 | $18 | $114 |
| PSA test (prostate cancer screening) | 111 | $18 | $94 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 111 | $132 | $3,675 |
| Infusion into a vein for hydration, each additional hour | 109 | $10 | $75 |
| CT scan of abdomen and pelvis with contrast | 106 | $168 | $1,067 |
| Unclassified drugs | 102 | $1 | $9 |
| Office visit, established patient, complex (40-54 min) | 100 | $124 | $496 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 88 | $90 | $657 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 87 | $1,107 | $4,802 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 69 | $175 | $700 |
| CT scan of chest, without contrast | 63 | $43 | $686 |
| New patient office visit (45-59 min) | 57 | $120 | $565 |
| Blood creatinine level | 53 | $5 | $31 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | 41 | $173 | $700 |
| Application of on-body injector for under skin injection | 35 | $14 | $96 |
| Ct scan of abdomen and pelvis without contrast | 33 | $65 | $560 |
| Drawing of blood for a medical problem | 27 | $62 | $264 |
| Ct scan of abdomen with contrast | 21 | $119 | $793 |
| Administration of chemotherapy into vein using push technique | 21 | $72 | $500 |
| Magnesium level test | 20 | $7 | $29 |
| Infusion into a vein for hydration, 31-60 minutes | 19 | $25 | $256 |
| Hospital follow-up visit, moderate complexity | 16 | $61 | $247 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
28.6% high complexity
67.0% medium
4.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$131,454
Total received (2018-2024)
Avg $18,779/year across 7 years
Top 11% in TX for medical oncology
38
Companies
167
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$109,213 (83.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$20,358 (15.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,883 (1.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,366
2023$3,202
2022$30,652
2021$63,486
2020$14,240
2019$8,871
2018$7,638
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Myriad Genetic Laboratories, Inc.
$92,874
AstraZeneca Pharmaceuticals LP
$9,768
Bayer HealthCare Pharmaceuticals Inc.
$4,375
Rigel Pharmaceuticals, Inc.
$3,975
Mylan Inc.
$3,832
Karyopharm Therapeutics Inc.
$2,250
Seattle Genetics, Inc.
$1,842
ARRAY BIOPHARMA INC
$1,575
BeiGene USA, Inc.
$1,312
Epizyme, Inc.,
$1,250
Celgene Corporation
$1,238
Exelixis Inc.
$1,225
PharmaEssentia USA Corporation
$1,100
Daiichi Sankyo Inc.
$1,055
G1 Therapeutics, Inc.
$778
EMD Serono, Inc.
$500
BeiGene, Ltd.
$450
Astellas Pharma US Inc
$344
Pharmacyclics LLC, An AbbVie Company
$331
GlaxoSmithKline, LLC.
$153
JAZZ PHARMACEUTICALS INC.
$149
Puma Biotechnology, Inc.
$147
PUMA BIOTECHNOLOGY, INC.
$125
TESARO, Inc.
$124
PFIZER INC.
$123
ABBVIE INC.
$119
E.R. Squibb & Sons, L.L.C.
$110
Medtronic USA, Inc.
$106
Pharming Healthcare, Inc.
$52
Tempus AI, Inc
$41
Pharmacyclics LLC, an AbbVie Company
$25
Myovant Sciences Inc.
$24
Takeda Pharmaceuticals U.S.A., Inc.
$16
Abbott Laboratories
$14
Novartis Pharmaceuticals Corporation
$14
Incyte Corporation
$14
Gilead Sciences, Inc.
$12
Secura Bio, Inc.
$12
Top 3 companies account for 81.4% of total payments
Associated products mentioned in payments ›
Aliqopa · BESREMI · BRAC CDx · BRACAnalysis · BRAFTOVI · BRUKINSA · COSELA · Cabometyx · EMPLICITI · ENHERTU · EPKINLY · EndoPredict · FRUZAQLA · Farydak · IMBRUVICA · IMFINZI · Imbruvica · JAKAFI · KISQALI · LYNPARZA · MYCHOICE CDX · MYRISK · NERLYNX · Nerlynx · OPDIVO · ORGOVYX · OSTEOCOOL RF ABLATION · PERCLOSE PROGLIDE · PRECISETUMOR · PreciseTumor · SPRYCEL · TAGRISSO · TAZVERIK · Tavalisse · Tepmetko · Vitrakvi · XOSPATA · XPOVIO · XT CDX · Xospata · ZEJULA · ZEPZELCA · myChoice CDx · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (83%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $57 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
3
Per 100K population
5.9
County median income
$61,122
Nearest hospital
PARIS REGIONAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Prakash is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), and high industry engagement (consulting-driven, top 11%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Prakash experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Prakash performed 58,650 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Prakash receive payments from pharmaceutical companies?
Yes. Dr. Prakash received a total of $131,454 from 38 companies across 167 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Prakash's costs compare to other medical oncologys in Paris?
Dr. Prakash's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Prakash) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Paris
Browse medical oncologys in Paris ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc..
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology